( TorontoVE:QPT )

News from Quest PharmaTech Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

18 May, 2017, 07:00 ET Madenco Biosciences Creates New Line of Cosmeceuticals to Complement Bellus Skin™ Serum for Anti-Aging

TSX Venture: QPT EDMONTON, May 18, 2017 /PRNewswire/ - Madenco Biosciences Inc. ("Madenco"), a subsidiary of Quest PharmaTech Inc. (TSX-V: QPT)...


09 May, 2017, 07:00 ET OncoQuest Announces Enrollment of First Patient in Phase 1/2 Clinical Study Using Combination of Oregovomab with Checkpoint Inhibitor Nivolumab in Recurrent Ovarian Cancer

EDMONTON, May 9, 2017 /PRNewswire/ - OncoQuest Inc. ("OncoQuest"), a biopharmaceutical company focused on the development and commercialization of...


04 May, 2017, 11:34 ET Quest PharmaTech Expands Its Consumer Health Product Pipeline with Clinically Validated Natural Allergy Relief

Investment in Natural Rf Life Sciences Inc. managed by CEO Dr. Jacqueline Shan TSX Venture: QPT EDMONTON, May 4, 2017 /PRNewswire/ - Quest...


07 Dec, 2016, 16:31 ET OncoQuest Initiates Commercial Scale Oregovomab Manufacturing Program for Treatment of Ovarian Cancer

- Signs Agreement with Cytovance for Development of Commercial Scale Antibody Manufacturing, and with Veristat for Clinical Trial Management...


29 Nov, 2016, 17:00 ET OncoQuest Announces Positive Interim Results from Its Phase 2b Clinical Study

- Oregovomab in Combination with Chemotherapy Improves Clinical Outcome in Ovarian Cancer Patients TSX Venture: QPT EDMONTON, Nov. 29, 2016...


02 Nov, 2016, 09:30 ET OncoVent Initiates Clinical Development Program for Anti-MUC1 MAb AR20.5 for Treatment of Pancreatic Cancer

Signed Agreement with Cell Culture Company (C3) for Manufacturing of Clinical Grade Antibody to Support Planned Clinical Studies EDMONTON, Nov. 2,...


20 Oct, 2016, 09:30 ET Anti-MUC1 MAb AR20.5 Induces Specific Cell Mediated Immune Response to MUC1 Antigen in Pre-Clinical Pancreatic Cancer Model

Abstract of the study wins "Scholar-in Training Award" for presentation at the AACR Special Conference on Tumor Immunology and Immunotherapy in...


06 Sep, 2016, 15:21 ET Quest PharmaTech Inc. Retains Haft Group for Financial Services

TSX Venture: QPT EDMONTON, Sept. 6, 2016 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company...


22 Mar, 2016, 09:30 ET Quest PharmaTech's Subsidiary, OncoQuest, Signs Agreement with Shenzhen Hepalink Pharmaceutical Co., Ltd. to Fund Immunotherapy for Treatment of Cancer in China

TSX Venture: QPT EDMONTON, March 22, 2016 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company...


18 Nov, 2015, 11:22 ET Quest PharmaTech's Subsidiary, OncoQuest, Closes U.S. $13,000,000 Preferred Share Private Placement with Hepalink USA to Fund Immunotherapy for Treatment of Cancer

Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of...


18 Nov, 2015, 09:30 ET Quest PharmaTech's Subsidiary, OncoQuest, Closes U.S. $13,000,000 Preferred Share Private Placement with Hepalink USA to Fund Immunotherapy for Treatment of Cancer

TSX Venture: QPT EDMONTON, Nov. 18, 2015 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company...


13 Jan, 2015, 09:30 ET Quest PharmaTech Announces Funding Support from National Research Council's Industrial Research Assistance Program for IgE Antibody Cancer Immunotherapy Development (AllergoOncology)

TSX Venture: QPT EDMONTON, Jan. 13, 2015 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical...


22 Oct, 2014, 13:34 ET Quest PharmaTech to Market and Distribute Premium Anti-Wrinkle Skin Care Product, Bellus Skin™; Dr. Jacqueline Shan, Creator of COLD FX®, to Assist

TSX Venture: QPT EDMONTON, Oct. 22, 2014 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company...


09 Jun, 2014, 12:59 ET Quest PharmaTech Completes Patient Enrollment in Phase IIb Study of Oregovomab for the Immunotherapy of Ovarian Cancer

TSX Venture: QPT EDMONTON, June 9, 2014 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company...


23 Jul, 2013, 09:30 ET Quest PharmaTech Establishes Joint Venture with Korean-Based AD Biotech Co., Ltd. to Develop Immunotherapeutic Products for Cancer

TSX Venture: QPT EDMONTON, July 23, 2013 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company...


08 Apr, 2013, 19:00 ET Quest PharmaTech Signs Exclusive License Agreement with UCLA for anti - PSA IgE Technology; UCLA researchers to present anti - PSA IgE preclinical data at the 2013 American Association for Cancer Research Conference

TSX Venture: QPT EDMONTON, April 8, 2013 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company...


22 Jan, 2013, 09:30 ET Quest PharmaTech Enrolls 40th Patient in its Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial for Ovarian Cancer in Italy and the U.S.

TSX Venture: QPT EDMONTON, Jan. 22, 2013 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company...


02 Oct, 2012, 09:30 ET Quest PharmaTech Acquires Immunoglobulin E Technology to Strengthen its Combination Therapy Approach for the Treatment of Cancer

TSX Venture: QPT EDMONTON, Oct. 2, 2012 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company...


10 Jul, 2012, 09:30 ET Quest PharmaTech Updates Progress of Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial in Italy

TSX Venture: QPT EDMONTON, July 10, 2012 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company...


14 Jun, 2012, 09:30 ET Quest PharmaTech Initiates Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial in United States

TSX Venture: QPT EDMONTON, June 14, 2012 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company...


05 Jun, 2012, 13:29 ET Quest PharmaTech Announces Signing of $8,000,000 Investment Agreement to Support Oregovomab Clinical Trial Programs

TSX Venture: QPT EDMONTON, June 5, 2012 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company...


29 Nov, 2011, 09:30 ET Quest PharmaTech Announces Development of Second Generation Photodynamic Therapy Products for the Treatment of Cancer based on Nanotechnology

EDMONTON, Nov. 29, 2011 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a biotechnology company developing and...


01 Nov, 2011, 09:30 ET Quest PharmaTech Announces Oregovomab Presentation at Biennial Meeting of Asian Society of Gynecologic Oncology (ASGO 2011)

TSX Venture: QPT EDMONTON, Nov. 1, 2011 /PRNewswire/ - Quest PharmaTech Inc. (TSXV: QPT) ("Quest" or the "Company"), a pharmaceutical company...


21 Jul, 2011, 11:59 ET Quest PharmaTech Announces Allowance of US Patent for the use of Immunotherapeutic Antibodies in Combination with Chemotherapy for the Treatment of Cancer

TSX Venture: QPT EDMONTON, July 21, 2011 /PRNewswire/ - Quest PharmaTech Inc. (TSXV: QPT) ("Quest" or the "Company"), a pharmaceutical company...